Dynavax Technologies Company Profile (NASDAQ:DVAX)

About Dynavax Technologies (NASDAQ:DVAX)

Dynavax Technologies logoDynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma. Its products include HEPLISAV-B, AZD1419, SD-101, DV281, DV230F and DV1001. HEPLISAV-B is an investigational adult hepatitis B vaccine. AZD1419 is being developed for the treatment of asthma. SD-101 is an investigational TLR9 agonist designed to elicit a potent and focused immune response to cancer. DV281 is an investigational TLR9 agonist designed specifically for focused delivery to primary lung tumors and lung metastases. DV230F is indicated for the treatment of Liver Tumors. DV1001 targets TLR 7 and 8 agonist for multiple malignancies. DV230F and DV1001 are in pre-clinical stage of development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:DVAX
  • CUSIP: 26815810
  • Web: www.dynavax.com
Capitalization:
  • Market Cap: $278.12 million
  • Outstanding Shares: 48,793,000
Average Prices:
  • 50 Day Moving Avg: $5.55
  • 200 Day Moving Avg: $5.12
  • 52 Week Range: $3.20 - $17.50
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.10
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $10.25 million
  • Price / Sales: 27.13
  • Book Value: $2.14 per share
  • Price / Book: 2.66
Profitability:
  • EBIDTA: ($103,440,000.00)
  • Net Margins: -2,650.25%
  • Return on Equity: -78.57%
  • Return on Assets: -65.94%
Debt:
  • Current Ratio: 3.86%
  • Quick Ratio: 3.86%
Misc:
  • Average Volume: 1.30 million shs.
  • Beta: 1.94
  • Short Ratio: 3.14
 

Frequently Asked Questions for Dynavax Technologies (NASDAQ:DVAX)

What is Dynavax Technologies' stock symbol?

Dynavax Technologies trades on the NASDAQ under the ticker symbol "DVAX."

How were Dynavax Technologies' earnings last quarter?

Dynavax Technologies Co. (NASDAQ:DVAX) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.60) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.60). The business had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.75 million. Dynavax Technologies had a negative return on equity of 78.57% and a negative net margin of 2,650.25%. During the same quarter in the previous year, the company posted ($0.70) earnings per share. View Dynavax Technologies' Earnings History.

Where is Dynavax Technologies' stock going? Where will Dynavax Technologies' stock price be in 2017?

3 analysts have issued 1 year price objectives for Dynavax Technologies' shares. Their forecasts range from $7.00 to $45.00. On average, they anticipate Dynavax Technologies' stock price to reach $21.25 in the next year. View Analyst Ratings for Dynavax Technologies.

What are analysts saying about Dynavax Technologies stock?

Here are some recent quotes from research analysts about Dynavax Technologies stock:

  • 1. Cowen and Company analysts commented, "DVAX announced that it will undergo corporate restructuring, resulting in an ~40%." (1/6/2017)
  • 2. According to Zacks Investment Research, "Dynavax Technologies discovers, develops, and intends to commercialize innovative products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases using versatile, proprietary approaches that alter immune system responses in highly specific ways. Dynavax's clinical development programs are based on immunostimulatory sequences which are short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation. " (11/28/2016)

Who are some of Dynavax Technologies' key competitors?

Who owns Dynavax Technologies stock?

Dynavax Technologies' stock is owned by a variety of of institutional and retail investors. Top institutional investors include GMT Capital Corp (5.29%), SENVEST MANAGEMENT, LLC (4.85%), Vanguard Group Inc. (4.12%), Blair William & Co. IL (3.04%), FMR LLC (2.67%) and Kornitzer Capital Management Inc. KS (2.48%). Company insiders that own Dynavax Technologies stock include Eddie Gray and Robert Janssen. View Institutional Ownership Trends for Dynavax Technologies.

Who sold Dynavax Technologies stock? Who is selling Dynavax Technologies stock?

Dynavax Technologies' stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., FMR LLC, TIAA CREF Investment Management LLC, Morgan Stanley, Credit Suisse AG, Redmile Group LLC, Schwab Charles Investment Management Inc. and UBS Asset Management Americas Inc.. View Insider Buying and Selling for Dynavax Technologies.

Who bought Dynavax Technologies stock? Who is buying Dynavax Technologies stock?

Dynavax Technologies' stock was bought by a variety of institutional investors in the last quarter, including GMT Capital Corp, Point72 Asset Management L.P., Kornitzer Capital Management Inc. KS, Paulson & CO. Inc., Quantitative Investment Management LLC, Vanguard Group Inc., Endurant Capital Management LP and Renaissance Technologies LLC. Company insiders that have bought Dynavax Technologies stock in the last two years include Eddie Gray and Robert Janssen. View Insider Buying and Selling for Dynavax Technologies.

How do I buy Dynavax Technologies stock?

Shares of Dynavax Technologies can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Dynavax Technologies stock cost?

One share of Dynavax Technologies stock can currently be purchased for approximately $5.70.

Analyst Ratings

Consensus Ratings for Dynavax Technologies (NASDAQ:DVAX) (?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $21.25 (272.85% upside)

Analysts' Ratings History for Dynavax Technologies (NASDAQ:DVAX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/9/2017Royal Bank of CanadaBoost Price TargetSector Perform -> Sector Perform$6.00 -> $7.00HighView Rating Details
1/6/2017Cowen and CompanyReiterated RatingBuy$45.00N/AView Rating Details
11/19/2016William BlairReiterated RatingOutperform$45.00 -> $17.00N/AView Rating Details
9/2/2016S&P Equity ResearchBoost Price Target$11.28 -> $16.01N/AView Rating Details
4/27/2016JPMorgan Chase & Co.DowngradeOverweight -> Neutral$29.00 -> $22.00N/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Dynavax Technologies (NASDAQ:DVAX)
Earnings by Quarter for Dynavax Technologies (NASDAQ:DVAX)
Earnings History by Quarter for Dynavax Technologies (NASDAQ:DVAX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.60)($0.60)$0.75 million$0.15 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.85)($0.56)$2.90 million$7.30 millionViewN/AView Earnings Details
11/7/2016Q3($0.75)($0.90)$2.44 million$0.20 millionViewN/AView Earnings Details
8/5/2016Q2($0.68)($0.75)$1.58 million$2.65 millionViewN/AView Earnings Details
5/9/2016Q1($0.63)($0.70)$627.00 million$942.00 millionViewN/AView Earnings Details
3/8/2016Q4($0.75)($0.70)$1.15 million$0.69 millionViewN/AView Earnings Details
11/5/2015Q3($0.78)($0.82)$1.65 million$1.20 millionViewN/AView Earnings Details
8/7/2015Q2($1.00)($0.80)$3.05 million$1.55 millionViewN/AView Earnings Details
5/7/2015Q1 2015($0.95)($0.97)$1.26 million$0.63 millionViewN/AView Earnings Details
3/5/2015Q4 2014($1.06)($0.85)$2.15 million$2.28 millionViewN/AView Earnings Details
11/5/2014Q314($0.09)($0.11)$2.50 million$2.21 millionViewN/AView Earnings Details
8/7/2014Q214($0.06)($0.09)$2.26 million$3.05 millionViewN/AView Earnings Details
5/5/2014Q1 2014($0.06)($0.05)$4.22 million$3.50 millionViewN/AView Earnings Details
3/10/2014Q413($0.07)($0.09)$1.56 million$2.80 millionViewN/AView Earnings Details
11/7/2013Q313($0.10)($0.09)$1.83 million$2.93 millionViewN/AView Earnings Details
7/29/2013Q2 2013($0.10)($0.09)$2.91 million$3.40 millionViewN/AView Earnings Details
5/6/2013Q113($0.11)($0.11)$2.40 million$2.10 millionViewN/AView Earnings Details
3/1/2013Q4 2012($0.11)$11.40 million$1.80 millionViewN/AView Earnings Details
11/1/2012Q312($0.08)($0.10)$5.00 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Dynavax Technologies (NASDAQ:DVAX)
2017 EPS Consensus Estimate: ($2.00)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.46)($0.46)($0.46)
Q2 20171($0.44)($0.44)($0.44)
Q3 20171($0.43)($0.43)($0.43)
Q4 20171($0.67)($0.67)($0.67)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Dynavax Technologies (NASDAQ:DVAX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Dynavax Technologies (NASDAQ:DVAX)
Insider Ownership Percentage: 2.00%
Institutional Ownership Percentage: 84.61%
Insider Trades by Quarter for Dynavax Technologies (NASDAQ:DVAX)
Institutional Ownership by Quarter for Dynavax Technologies (NASDAQ:DVAX)
Insider Trades by Quarter for Dynavax Technologies (NASDAQ:DVAX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/24/2017Robert JanssenVPBuy6,000$4.04$24,240.00View SEC Filing  
6/28/2016Robert JanssenVPBuy1,452$13.68$19,863.36View SEC Filing  
5/20/2016Eddie GrayCEOBuy2,750$15.57$42,817.50View SEC Filing  
5/12/2016Robert JanssenVPBuy1,000$15.12$15,120.00View SEC Filing  
8/14/2014Eddie GrayCEOBuy25,000$1.49$37,250.00View SEC Filing  
10/30/2013Peggy V PhillipsDirectorBuy93,023$1.08$100,464.84View SEC Filing  
9/14/2012Jennifer LewVPSell18,750$4.53$84,937.50View SEC Filing  
9/13/2012Robert CoffmanVPSell8,000$4.52$36,160.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Dynavax Technologies (NASDAQ:DVAX)
Latest Headlines for Dynavax Technologies (NASDAQ:DVAX)
Source:
DateHeadline
finance.yahoo.com logoDynavax to Present Data on SD-101 in Combination with KEYTRUDA(R) at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
finance.yahoo.com - May 19 at 8:11 AM
bizjournals.com logoBiotech Stocks on Investors' Radar -- Progenics Pharma, Dynavax Technologies, Intrexon, and Heat Biologics
www.bizjournals.com - May 12 at 3:48 PM
finance.yahoo.com logoETFs with exposure to Dynavax Technologies Corp. : May 11, 2017
finance.yahoo.com - May 11 at 5:29 PM
americanbankingnews.com logoWilliam Blair Comments on Dynavax Technologies Co.'s Q2 2017 Earnings (DVAX)
www.americanbankingnews.com - May 11 at 8:50 AM
finance.yahoo.com logoDynavax Technologies Corp. :DVAX-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 5:00 PM
americanbankingnews.com logo$700,000.00 in Sales Expected for Dynavax Technologies Co. (DVAX) This Quarter
www.americanbankingnews.com - May 10 at 9:13 AM
americanbankingnews.com logoZacks: Brokerages Expect Dynavax Technologies Co. (DVAX) to Post -$0.56 EPS
www.americanbankingnews.com - May 9 at 12:23 AM
americanbankingnews.com logoDynavax Technologies Co. (DVAX) Announces Earnings Results, Hits Expectations
www.americanbankingnews.com - May 8 at 2:00 PM
finance.yahoo.com logoDynavax Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 9:20 AM
finance.yahoo.com logoDynavax Technologies reports 1Q loss
finance.yahoo.com - May 8 at 9:20 AM
americanbankingnews.com logoDynavax Technologies (DVAX) Given Daily Media Impact Rating of 0.56
www.americanbankingnews.com - May 3 at 11:52 AM
americanbankingnews.com logoDynavax Technologies (DVAX) Earns Media Impact Score of 0.43
www.americanbankingnews.com - April 30 at 2:22 PM
americanbankingnews.com logoDynavax Technologies (DVAX) Given News Impact Score of 0.18
www.americanbankingnews.com - April 27 at 10:54 PM
americanbankingnews.com logoDynavax Technologies (DVAX) Receiving Somewhat Negative Press Coverage, Study Shows
www.americanbankingnews.com - April 24 at 2:22 PM
americanbankingnews.com logoDynavax Technologies (DVAX) Receives News Impact Rating of 0.44
www.americanbankingnews.com - April 21 at 6:48 PM
finance.yahoo.com logoETFs with exposure to Dynavax Technologies Corp. : April 21, 2017
finance.yahoo.com - April 21 at 4:54 PM
americanbankingnews.com logoDynavax Technologies Co. (DVAX) Expected to Post Quarterly Sales of $750,000.00
www.americanbankingnews.com - April 20 at 3:25 PM
americanbankingnews.com logoZacks: Analysts Expect Dynavax Technologies Co. (DVAX) to Post -$0.56 Earnings Per Share
www.americanbankingnews.com - April 18 at 10:31 AM
americanbankingnews.com logoVery Favorable News Coverage Extremely Likely to Impact Dynavax Technologies (DVAX) Stock Price
www.americanbankingnews.com - April 17 at 9:43 AM
seekingalpha.com logoBiotech Forum Daily Digest: What's Next For Dynavax? Akorn On The Block?
seekingalpha.com - April 10 at 11:51 AM
seekingalpha.com logoMy Latest Take On Dynavax Technololgies
seekingalpha.com - April 7 at 4:48 PM
investopedia.com logoWilliam Blair Assigns 70% Probability of Approval to Dynavax's Heplisav (DVAX)
www.investopedia.com - April 7 at 4:48 PM
finance.yahoo.com logoWilliam Blair Assigns 70% Probability of Approval to Dynavax's Heplisav
finance.yahoo.com - April 7 at 4:48 PM
finance.yahoo.com logoETFs with exposure to Dynavax Technologies Corp. : April 7, 2017
finance.yahoo.com - April 7 at 4:48 PM
us.rd.yahoo.com logoWhat Dynavax Technologies Holders Need to Consider Heading Into the Heplisav-B PDUFA
us.rd.yahoo.com - April 3 at 5:11 PM
fool.com logoWhy Dynavax Technologies Corporation Stock Briefly Spiked Today
www.fool.com - April 3 at 10:10 AM
finance.yahoo.com logoDynavax Announces FDA Advisory Committee Meeting to Review HEPLISAV-B
finance.yahoo.com - April 3 at 6:29 AM
seekingalpha.com logo2 Attractive Biotech Stocks Under $10 For Spring
seekingalpha.com - March 23 at 5:24 PM
us.rd.yahoo.com logoDynavax Announces Upcoming Data Presentations for Three TLR9 Agonist Programs at the 2017 American Association for Cancer Research Annual Meeting
us.rd.yahoo.com - March 21 at 8:17 AM
streetinsider.com logoDynavax (DVAX) Announces Data Presentations for Three TLR9 ... - StreetInsider.com
www.streetinsider.com - March 20 at 7:45 PM
finance.yahoo.com logoDYNAVAX TECHNOLOGIES CORP Financials
finance.yahoo.com - March 17 at 5:08 PM
americanbankingnews.com logoWilliam Blair Weighs in on Dynavax Technologies Co.’s FY2017 Earnings (DVAX)
www.americanbankingnews.com - March 16 at 2:06 PM
seekingalpha.com logoDynavax Technologies Corporation (DVAX)
seekingalpha.com - March 13 at 4:55 PM
biz.yahoo.com logoDYNAVAX TECHNOLOGIES CORP Files SEC form 10-K, Annual Report
biz.yahoo.com - March 13 at 4:55 PM
biz.yahoo.com logoDYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
biz.yahoo.com - March 13 at 4:55 PM
us.rd.yahoo.com logoDynavax Reports Fourth Quarter and Year End 2016 Financial Results and Company Update
us.rd.yahoo.com - March 13 at 12:02 PM
seekingalpha.com logoDynavax Technologies (DVAX) Presents At Cowen and Company 37th Annual Health Care Conference
seekingalpha.com - March 7 at 4:44 PM
biz.yahoo.com logoDYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 6 at 4:37 PM
marketwatch.com logoDynavax shares fall 4% premarket after company releases data from melanoma trial
www.marketwatch.com - March 6 at 10:05 AM
finance.yahoo.com logoDynavax Presents Promising Clinical Data from Lead Immuno-Oncology Candidate, SD-101, at the International Congress on Targeted Anticancer Therapies
finance.yahoo.com - March 6 at 10:05 AM
finance.yahoo.com logo8:02 am Dynavax announces the presentation of findings in patients with metastatic melanoma in the dose escalation phase of an ongoing Phase 1b/2 study investigating SD-101 at the International Congress on Targeted Anticancer Therapies
finance.yahoo.com - March 6 at 10:05 AM
marketwatch.com logoUPDATE: Dynavax shares reverse premarket losses to open flat
www.marketwatch.com - March 6 at 10:05 AM
benzinga.com logoMid-Day Market Update: Dow Rises Over 250 Points; Palo Alto Shares Plunge
www.benzinga.com - March 2 at 5:05 PM
us.rd.yahoo.com logoDynavax to Present at the Cowen and Company 37th Annual Health Care Conference
us.rd.yahoo.com - March 2 at 5:05 PM
seekingalpha.com logoBiotech Forum Daily Digest: Revisiting Eagle Pharma; Can Biotech Finally Break Through Upward Resistance Levels?
seekingalpha.com - March 1 at 9:35 PM
marketwatch.com logoDynavax stock surges 53% on new FDA review of Hep B vaccine and Trump statements about FDA deregulation
us.rd.yahoo.com - March 1 at 4:34 PM
us.rd.yahoo.com logo4:03 pm Dynavax: FDA has accepted for review its responses to the CRL issued by the FDA in November 2016 for the Biologics License Application for HEPLISAV-B; PDUFA action date of August 10, 2017
us.rd.yahoo.com - March 1 at 12:53 PM
biz.yahoo.com logoDYNAVAX TECHNOLOGIES CORP Files SEC form 8-K, Change in Directors or Principal Officers, Other Events, Financial Stat
us.rd.yahoo.com - March 1 at 12:53 PM
fool.com logoWhy Dynavax Technologies Corporation Stock Is Skyrocketing Today
www.fool.com - March 1 at 9:49 AM
finance.yahoo.com logoDynavax Announces FDA Acceptance for Review of Its Complete Response to November 2016 CRL and PDUFA Action Date for HEPLISAV-B(TM)
finance.yahoo.com - February 28 at 5:02 PM

Social

Chart

Dynavax Technologies (DVAX) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff